SCHEDULE: Sio Capital Discloses 5.05% Stake in Aprea Therapeutics

Sio Capital Management, LLC has filed an Amendment No. 3 to its Schedule 13G, reporting a 5.05% beneficial ownership stake in Aprea Therapeutics, Inc. as of June 30, 2025.

Summary

• Sio Capital Management, LLC reported beneficial ownership of 279,369 shares of Aprea Therapeutics, Inc. common stock.
• This represents 5.05% of the outstanding common stock.
• The ownership is based on 5,525,172 shares of common stock outstanding as of April 22, 2025, as reported by Aprea Therapeutics in its Form 8-K filed on June 9, 2025.
• Sio Capital Management, LLC, an investment adviser, holds these shares with shared voting and shared dispositive power.
• The filing is an Amendment No. 3 to a previously filed Schedule 13G.

Sentiment

Score: 6

Explanation: The filing indicates that Sio Capital Management, LLC continues to hold a significant beneficial ownership stake (5.05%) in Aprea Therapeutics, suggesting ongoing confidence from an institutional investor. However, as an amendment, it doesn't necessarily signal a new, aggressive investment, but rather an update to an existing position.

Positives

• An institutional investment adviser, Sio Capital Management, LLC, maintains a significant stake (5.05%) in Aprea Therapeutics, indicating continued interest or confidence.
• The beneficial ownership is above the 5% threshold, signifying a notable position.

Future Outlook

NA

Industry Context

This filing reflects an institutional investor's continued stake in a biotechnology company, a common occurrence in the sector where specialized funds often take positions in promising therapeutic developers.

Stakeholder Impact

• Shareholders: The continued significant stake by an institutional investor may be viewed positively, potentially signaling confidence in the company.

Key Dates

Recommendation

This Schedule 13G Amendment No. 3 indicates that Sio Capital Management, LLC maintains a 5.05% beneficial ownership in Aprea Therapeutics. While the presence of an institutional investor holding a significant stake can be a positive signal, this filing is purely an ownership disclosure and does not provide new financial performance data, strategic updates, or operational insights into Aprea Therapeutics. Therefore, it primarily confirms an existing institutional position rather than providing new information that would warrant a change in investment thesis. Investors should consider this information as part of a broader due diligence process, looking at the company's financial results, pipeline, and market conditions before making a definitive investment decision.

Keywords

Aprea Therapeutics, Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Institutional Investor